Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 14/20 | 0.39 |
| ▸ | MASP2 | O00187 | 7/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6773854 | 1.00 | F2 (0.39) | F2MASP2PSEN1PSEN2APH1B | |
| SCHEMBL6771739 | 1.00 | F2 (0.39) | F2MASP2PSEN1PSEN2APH1B | |
| SCHEMBL6768540 | 0.86 | PSEN1 (0.38) | F2MASP2PSEN1PSEN2APH1B | |
| SCHEMBL6773274 | 0.80 | PSEN1 (0.39) | MASP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6768537 | 0.79 | PSEN1 (0.38) | MASP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6772193 | 0.79 | PSEN1 (0.38) | MASP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6426665 | 0.78 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4985855 | 0.77 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6388119 | 0.77 | CYP2C19 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6768524 | 0.77 | EED (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696438-B2 | AMYLOID PRECURSOR PROTEIN ANTAGONISTS, 3-((N'-(3-PYRIDINOYL)-L -ALANINYL)-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO-2H-3-BENZAZEPIN-2-ONE, USED FOR PROPHYLAXIS OF NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030162768-A1 | Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | AUDIA JAMES E (US) | 2003-08-28 | — | — | US | disclosed |
| US-6528505-B1 | Treating Alzheimer's disease;5-(S)-(N'-(L-prolyl)-L-alaninyl)-amino-7-methyl-5,7-di hydro-6H- dibenz(b,d)azepin-one | ELAN PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162768-A1 | Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, IAPP, BACE1 | F2 3303/4885MASP2 510/4885PSEN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.